Servier Stumbles in Muscle Disease as Drug From $1.5B Deal Fails Pivotal Test

T2Covered by 1 source · first reported by Fierce Biotech / Fierce Healthcare / MedCity / GEN at 04 Nov, 18:52 UTC

Servier’s sevasemten came from the acquisition of the muscular dystrophy assets of Edgewise Therapeutics. While the small molecule had met the goal of a Phase 2 test in Becker muscular dystrophy, Servier said new results in a pivotal cohort do not show statistically significant benefit. The post…

businessscience

Sources

• T2Servier Stumbles in Muscle Disease as Drug From $1.5B Deal Fails Pivotal TestFierce Biotech / Fierce Healthcare / MedCity / GEN04 Nov, 18:52